Bloomberg News

Adcock Says Synap Forte Clinical Trial Shows No Heart Effects

October 26, 2011

Oct. 26 (Bloomberg) -- Adcock Ingram Holdings Ltd. said a clinical study of its Synap Forte medicine, which contains dextropropoxyphene, showed no signs of cardiotoxicity.

Adcock is appealing a decision by South Africa’s Medicines Control Council to withdraw products containing dextropropoxyphene. It is allowed to continue selling Synap Forte, Lentogesic and Doxyfene until the appeal is heard.

“The study results showed no significant difference in heart effects between Synap Forte and placebo,” Johannesburg- based Adcock said in a statement distributed by SAPA-PR.

Link to Statement:{NSN LTO17I3H0JK0 <GO>}

To contact the editor responsible for this story: Vernon Wessels at vwessels@bloomberg.net


China's Killer Profits
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus